The #1 performing stock this week is AAOI which gained +15% last week on the news the company is developing Electro-absorption Modulated Lasers (EMLs) operating at a data rate of 10 Gigabits per second (Gbps). Applied Optoelectronics’ 10 Gbps EMLs are designed specifically for 10GBASE-ZR Ethernet and cable TV (CATV) Remote PHY connectivity to enable deployment of the next-generation FTTH, telecom, and CATV networks. The lasers are available at wavelengths spanning the ITU-T C-band dense wavelength division multiplexing (DWDM) grid and are able to support fiber transmission distances up to 80km. They also feature a high laser chip operating temperature up to 55oC, enabling commercial and industrial operating temperature ranges for transceivers. AAOI is our play on the trend of datacenters switching from copper wire to faster optical lasers.
IMGN came in at spot #2 with a 70% gain since profiled on GuerillaStockTrading.com. The stock has been rising since the company announced that it will present at the AACR Anual Meeting on April 1, 2017. The company said it “will be presenting nine abstracts with preclinical data demonstrating technology advances that will enable us to continue to drive innovation in ADC approaches at AACR Annual Meeting.”
ImmunoGen presentations at AACR relate to:
Platform linker and payload innovations
Title: Comparison of site-specific and lysine-linked indolino-benzodiazepine antibody-drug conjugates (ADCs) abstract # 75
While site-specific conjugation can lead to improved efficacy and tolerability, the advantages and disadvantages of site-specific conjugation should be carefully considered for every ADC candidate.
Title: Bystander activity and in vivo efficacy of a folate receptor (FR )-targeting antibody-drug conjugate with a novel peptide linker abstract # 71
Folate receptor (FR ) is an antigen that is overexpressed on the cell surface of solid tumors including ovarian cancer. M9346A-NL-DM is a novel ADC, employing a new linker, with enhanced bystander activity and anti-tumor activity that can target tumors with heterogeneous expression of FR.
Title: Peptide-cleavable maytansinoid (ADCs) induce high bystander killing leading to improved anti-tumor activity in vivo abstract # 2186
A new promising type of maytansinoid ADC provides a high degree of bystander killing, improved activity in tumor models in vivo, and has a differentiated mechanism of metabolite release.
Title: Antibody-drug conjugates (ADCs) of peptide-linked Indolino-Benzodiazepine (IGN) DNA-alkylator provides improved anti-tumor activity over that of a crosslinker abstract # 53
Preclinical research shows that DNA-alkylating IGNs provide improved anti-tumor activity over that of a DNA-crosslinking ADC.
Preclinical research focused on novel targets
Title: Novel antibody-drug conjugates targeting ADAM9-expressing solid tumors demonstrate potent preclinical activity abstract #37ADAM9 is a promising cell surface target for antibody-drug conjugate development that is overexpressed in multiple solid tumor indications relative to corresponding normal tissues.
Title: Target validation, antibody discovery and preclinical data supporting ADAM9 as an antibody-drug conjugate therapeutic target for solid tumors abstract #38
These data demonstrate that anti-ADAM9 ADCs exhibit antitumor activity against a broad panel of ADAM9-positive malignancies and cause durable remissions in preclinical models at doses expected to be clinically achievable. Anti-ADAM9 ADCs represent a promising therapeutic strategy to a wide range of ADAM9-expressing tumors.
Title: In vitro and in vivo activity of a novel c-Met-targeting antibody-drug conjugate using a DNA-alkylating, indolinobenzodiazepine payload abstract #45c
Met dysregulation and/or overexpression are associated with tumor progression, metastasis and poor prognosis in numerous cancers. An anti-cMet antibody conjugated with the payload DGN549 exhibits compelling, c-Met targeted anti-cancer activity in vitro and in vivo, and represents a promising therapeutic strategy to deliver a potent cytotoxic agent to tumor cells bearing a wide range of c-Met expression.
Preclinical research focused on B-cell targets
Title: A novel CD19-targeting antibody-drug conjugate, huB4-DGN462, shows promising in vitro and in vivo activity in CD19-positive lymphoma models abstract #2651CD19 is a cell surface membrane protein expressed in most mature and immature B cell neoplasms, which make it a promising target for ADC therapy for B cell malignancies. A novel CD19-targeting ADC presents strong preclinical anti-lymphoma activity.
Title: Increased internalization and processing of the CD37-targeting antibody-drug conjugate, naratuximab emtansine (IMGN529), in the presence of rituximab leads to enhanced potency in diffuse large B-cell lymphoma models abstract #1073
Data show enhanced activity of rituximab plus IMGN529 combination in DLBCL models, supporting the clinical development of this combination.
The complete list of the top performing stocks for the week is below.